IRLAB strengthens patent protection for Phase IIb/III drug candidate mesdopetam ...Middle East

PR Newswire - News
IRLAB strengthens patent protection for Phase IIb/III drug candidate mesdopetam
STOCKHOLM, Dec. 8, 2020 /PRNewswire/ -- IRLAB (Nasdaq Stockholm: IRLAB A) announced today that the World Intellectual Property Organization, WIPO, has published a new patent application concerning drug candidate mesdopetam (IRL790). This composition of matter patent may extend the market...

Hence then, the article about irlab strengthens patent protection for phase iib iii drug candidate mesdopetam was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( IRLAB strengthens patent protection for Phase IIb/III drug candidate mesdopetam )

Apple Storegoogle play

Last updated :

Also on site :

Most viewed in News